Cancer drug interaction study: will antibiotics change how cediranib works?

NCT ID NCT00750841

Ongoing Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safety. The goal is to understand drug interactions, not to test if cediranib shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cediranib (experimental cancer drug) and rifampicin (antibiotic)
What this could lead to: If successful, this study could help doctors understand how to safely combine cediranib with other drugs that affect liver enzymes, potentially improving future dosing guidelines.
What could go wrong: This is an early, small Phase 1 study focused on drug interaction, not treatment effectiveness. It may not lead to any direct benefit for participants, and side effects from the drug combination are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Research Site

Edmonton, Alberta, T6G 1Z2, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Dundee, DD1 9SY, United Kingdom
Research Site

Glasgow, G12 0YN, United Kingdom
Research Site

London, NW1 2PG, United Kingdom
Research Site

London, SE1 9RT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.